Enact vs Accelerant
ACT and ARX side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACT and ARX compare
Enact is the larger company, worth 1.5 times as much as Accelerant ($6.5B against $4.3B).
Accelerant grew revenue faster over the last twelve months (54.6% versus 2.5% for Enact).
Enact pays a dividend yielding 1.9%; Accelerant does not pay one.
Enact scores higher on the StockData Score (6 against 1 for Accelerant), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACT | ARX |
|---|---|---|
| Size and price | ||
| Market cap | $6.5B | $4.3B |
| Share price | $47.18 | $19.82 |
| Change, 1 year | 35.1% | 68.8% |
| Change, 5 years | 103% | – |
| Beta (5Y) | 0.52 | 0.40 |
| Employees | 419 | – |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 4 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 0 | 0 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | 9.9× | – |
| P/S | 5.2× | 3.8× (better) |
| P/B | 1.2× (better) | 6.0× |
| PEG | 6.21 | – |
| Fair value | $108.87 | – |
| Margin of safety | 56.7% | – |
| Growth | ||
| Revenue growth (TTM) | 2.5% | 54.6% (better) |
| Revenue growth, 5Y average | 2.2% | – |
| EPS growth (TTM) | 8.2% (better) | −3267% |
| EPS growth, 5Y average | 14.8% | – |
| Financial health | ||
| Altman Z-score | 3.47 (better) | 0.21 |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | – |
| Years of dividend growth | 1 | – |
| Buyback yield | 6.5% | – |
| Shareholder yield | 8.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 21.7% | 29.7% |
| Held by insiders | 90.6% | 73.7% |
| Insider net buying, 12 months | −$280M | −$19.7M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 21.2% | 7.9% |
Go deeper
- ACT stock overview
- ACT income statement
- ACT valuation and score
- ARX stock overview
- ARX income statement
- ARX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.